DYN — Dyne Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.26bn
- $614.52m
- 31
- 23
- 12
- 10
Annual balance sheet for Dyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 345 | 377 | 256 | 123 | 642 |
| Prepaid Expenses | |||||
| Total Current Assets | 349 | 382 | 266 | 129 | 659 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.95 | 41 | 38.4 | 33.4 | 30 |
| Other Long Term Assets | |||||
| Total Assets | 353 | 426 | 306 | 165 | 691 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 11 | 28.7 | 28.1 | 51.1 | 42.3 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11 | 57.5 | 54 | 73.8 | 61.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 342 | 368 | 252 | 91.3 | 630 |
| Total Liabilities & Shareholders' Equity | 353 | 426 | 306 | 165 | 691 |
| Total Common Shares Outstanding |